ARS Pharmaceuticals/$SPRY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ARS Pharmaceuticals
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Ticker
$SPRY
Sector
Primary listing
Employees
161
Headquarters
Website
SPRY Metrics
BasicAdvanced
$833M
-
-$1.74
0.78
-
Price and volume
Market cap
$833M
Beta
0.78
52-week high
$18.90
52-week low
$6.66
Average daily volume
1.1M
Financial strength
Current ratio
7.278
Quick ratio
6.931
Long term debt to equity
147.486
Total debt to equity
147.486
Interest coverage (TTM)
-69.05%
Profitability
EBITDA (TTM)
-178.081
Gross margin (TTM)
60.13%
Net profit margin (TTM)
-203.25%
Operating margin (TTM)
-212.92%
Effective tax rate (TTM)
0.05%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
-33.04%
Return on equity (TTM)
-92.33%
Valuation
Price to revenue (TTM)
9.812
Price to book
7.29
Price to tangible book (TTM)
8.35
Price to free cash flow (TTM)
-4.83
Free cash flow yield (TTM)
-20.70%
Free cash flow per share (TTM)
-1.737
Growth
Revenue change (TTM)
-5.46%
Earnings per share change (TTM)
-2,275.03%
3-year revenue growth (CAGR)
300.09%
3-year earnings per share growth (CAGR)
26.09%
What the Analysts think about SPRY
Analyst ratings (Buy, Hold, Sell) for ARS Pharmaceuticals stock.
SPRY Financial Performance
Revenues and expenses
SPRY Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ARS Pharmaceuticals stock?
ARS Pharmaceuticals (SPRY) has a market cap of $833M as of March 15, 2026.
What is the P/E ratio for ARS Pharmaceuticals stock?
The price to earnings (P/E) ratio for ARS Pharmaceuticals (SPRY) stock is 0 as of March 15, 2026.
Does ARS Pharmaceuticals stock pay dividends?
No, ARS Pharmaceuticals (SPRY) stock does not pay dividends to its shareholders as of March 15, 2026.
When is the next ARS Pharmaceuticals dividend payment date?
ARS Pharmaceuticals (SPRY) stock does not pay dividends to its shareholders.
What is the beta indicator for ARS Pharmaceuticals?
ARS Pharmaceuticals (SPRY) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.